Delivery Order SPE2DR25D2014-SPE2DR26FZ60N
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Xhance 93 microgram nasal spray in 16-milliliter units. This is a firm fixed-price contract with a ceiling value of $1,241.25 and an ultimate completion date of November 12, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,724.52 to AmerisourceBergen Drug Corp for Xhance 93 mcg nasal spray (16mL) on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for Xhance 93 micrograms nasal spray (16 milliliters) with a ceiling value of $3,221.73. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 5, 2025, and performance at the vendor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,351.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XHANCE 93 mcg nasal spray (16 ml), with an ultimate completion date of September 23, 2025. This is a non-set-aside competitively awarded contract supporting federal medical procurement needs. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $16,960.28 to AmerisourceBergen Drug Corp for XHANCE 93 MCG Nasal Spray (16ML) on November 12, 2025, with an ultimate completion date of November 13, 2025. This competitively awarded, firm fixed price contract utilizes no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $5,049.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XHANCE 93 MCG nasal spray (16 mL) on November 5, 2025, with completion targeted for November 6, 2025. This competitive award, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $4,668.46 to AmerisourceBergen Drug Corp for XHANCE 93 MCG Nasal Spray (16ML) on August 8, 2025, with completion scheduled for August 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical supplier within the federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,134.11 to supply Xhance 93 MCG nasal spray (16 mL units) with an ultimate completion date of September 18, 2025. This non-competitive delivery order utilizes firm fixed pricing and was awarded on September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $1,212.30 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xhance 93 mcg nasal spray (16 mL). This firm fixed-price delivery order, which must be completed by August 11, 2025, represents a routine pharmaceutical procurement under the company's existing contract vehicle. The award was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $2,463.62 order is for Xhance 93 mcg nasal spray and has a completion date of March 25, 2024. Amerisourcebergen Drug Corp is the prime contractor on a larger indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00 through December 31,...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ60NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,662.60 to AmerisourceBergen Drug Corp for Xhance 93 mcg nasal spray (16ml) on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX) valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order represents a small-value transaction drawn from AmerisourceBergen's prime IDC and exemplifies the company's role in supplying specialized pharmaceutical products to support military healthcare operations. The contract's short completion timeline and firm pricing structure reflect the efficient delivery mechanisms established under the broader DLA Pharmaceutical Prime Vendor Global Program, which enables rapid fulfillment of medical supply requirements across federal healthcare systems. AmerisourceBergen's extensive portfolio of federal contract awards demonstrates its capability to meet diverse pharmaceutical procurement needs across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 11/3/25 |